The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
Subscribe To Our Newsletter & Stay Updated
